Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IDXX Stock Forecast 2026-2027
$571.21
Current Price
$45.61B
Market Cap
Buy 9
Hold 5
Sell 1
Wall St Analyst Ratings
Distance to IDXX Price Targets
+44.1%
To High Target of $823.00
+35.7%
To Median Target of $775.00
-17.7%
To Low Target of $470.00
IDXX Price Momentum
-6.1%
1 Week Change
-9.2%
1 Month Change
+40.6%
1 Year Change
-15.6%
Year-to-Date Change
-25.8%
From 52W High of $769.98
+60.4%
From 52W Low of $356.14
📊 TOP ANALYST CALLS
Did IDXX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if IDEXX is one of their latest high-conviction picks.
Latest IDXX Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, IDXX has a bullish consensus with a median price target of $775.00 (ranging from $470.00 to $823.00). The overall analyst rating is Buy (7.7/10). Currently trading at $571.21, the median forecast implies a 35.7% upside. This outlook is supported by 9 Buy, 5 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Steve Chesney at Atlantic Equities, suggesting a 17.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IDXX Analyst Ratings
9
Buy
5
Hold
1
Sell
IDXX Price Target Range
Low
$470.00
Average
$775.00
High
$823.00
Current: $571.21
Latest IDXX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IDXX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 9, 2026 | Piper Sandler | David Westenberg | Neutral | Maintains | $750.00 |
| Feb 5, 2026 | Barclays | Glen Santangelo | Overweight | Maintains | $800.00 |
| Feb 3, 2026 | BTIG | Mark Massaro | Buy | Maintains | $800.00 |
| Feb 3, 2026 | UBS | Andrea Alfonso | Neutral | Maintains | $730.00 |
| Dec 9, 2025 | Barclays | Glen Santangelo | Overweight | Initiates | $850.00 |
| Nov 4, 2025 | JP Morgan | Chris Schott | Overweight | Maintains | $775.00 |
| Nov 4, 2025 | BTIG | Mark Massaro | Buy | Maintains | $830.00 |
| Nov 4, 2025 | UBS | Andrea Alfonso | Neutral | Maintains | $750.00 |
| Nov 4, 2025 | Morgan Stanley | Erin Wright | Overweight | Maintains | $805.00 |
| Oct 31, 2025 | Stifel | Jonathan Block | Buy | Upgrade | $700.00 |
| Oct 1, 2025 | UBS | Andrea Alfonso | Neutral | Initiates | $720.00 |
| Aug 15, 2025 | Morgan Stanley | Erin Wright | Overweight | Maintains | $765.00 |
| Aug 11, 2025 | Piper Sandler | David Westenberg | Neutral | Maintains | $700.00 |
| Aug 4, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Aug 4, 2025 | JP Morgan | Chris Schott | Overweight | Maintains | $675.00 |
| Jul 29, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Jul 17, 2025 | Leerink Partners | Daniel Clark | Outperform | Maintains | $600.00 |
| Jul 2, 2025 | Stifel | Jonathan Block | Hold | Maintains | $540.00 |
| Jun 11, 2025 | Leerink Partners | Daniel Clark | Outperform | Maintains | $580.00 |
| May 19, 2025 | Stifel | Jonathan Block | Hold | Maintains | $510.00 |
IDEXX Laboratories, Inc. (IDXX) Competitors
The following stocks are similar to IDEXX based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
IDEXX Laboratories, Inc. (IDXX) Financial Data
IDEXX Laboratories, Inc. has a market capitalization of $45.61B with a P/E ratio of 43.6x. The company generates $4.30B in trailing twelve-month revenue with a 24.6% profit margin.
Revenue growth is +14.3% quarter-over-quarter, while maintaining an operating margin of +29.8% and return on equity of +66.2%.
Valuation Metrics
Market Cap
$45.61B
Enterprise Value
$46.28B
P/E Ratio
43.6x
PEG Ratio
2.5x
Price/Sales
10.6x
Growth & Margins
Revenue Growth (YoY)
+14.3%
Gross Margin
+60.3%
Operating Margin
+29.8%
Net Margin
+24.6%
EPS Growth
+14.8%
Financial Health
Cash/Price Ratio
+0.4%
Current Ratio
1.2x
Debt/Equity
60.8x
ROE
+66.2%
ROA
+25.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
IDEXX Laboratories, Inc. (IDXX) Business Model
About IDEXX Laboratories, Inc.
What They Do
Develops diagnostic products for veterinary and environmental markets.
Business Model
The company generates revenue by developing, manufacturing, and distributing a range of diagnostic products and services tailored for veterinary and environmental sectors. Its offerings include in-clinic laboratory analyzers, pet-side tests, and veterinary practice management software, which are sold to veterinarians and animal hospitals. Additionally, IDEXX provides water testing products and diagnostics for livestock, poultry, and dairy, further diversifying its income streams.
Additional Information
Founded in 1983 and based in Westbrook, Maine, IDEXX Laboratories has established itself as a leader in diagnostic innovation, supporting health monitoring for pets, agriculture, and public health globally. The company's commitment to advancing technology in diagnostics positions it well for future growth in the expanding veterinary and environmental markets.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
11,000
CEO
Mr. Jonathan J. Mazelsky
Country
United States
IPO Year
1991
Website
www.idexx.comIDEXX Laboratories, Inc. (IDXX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Mar 10, 2026
By Zacks Equity Research
Tale of the Tape
IDEXX Laboratories Stock Climbs 39.4% in a Year: What's Driving It?
IDXX shares jump 39% in a year, as CAG Diagnostics' recurring revenues, diagnostic innovations and software growth fuel momentum.
Mar 09, 2026
By Zacks Equity Research
Analyst Blog
SONVY vs. IDXX: Which Stock Should Value Investors Buy Now?
SONVY vs. IDXX: Which Stock Is the Better Value Option?
Mar 09, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
IDXX shares have increased by 39% over the past year, driven by strong recurring revenues from CAG Diagnostics and growth in diagnostic innovations and software.
Why It Matters
IDXX's 39% share increase reflects strong performance from CAG Diagnostics, indicating robust recurring revenues and growth in diagnostics and software, signaling potential for continued financial strength.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Zacks Premium offers Style Scores to help value, growth, and momentum investors identify strong stocks effectively.
Why It Matters
Zacks Style Scores enhance stock selection for various investment strategies, potentially leading to better returns and informed decision-making for investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors in Medical - Instruments stocks are considering SONOVA HOLDING (SONVY) and Idexx Laboratories (IDXX) for potential value opportunities.
Why It Matters
The comparison of SONOVA HOLDING and Idexx Laboratories indicates potential investment opportunities, affecting stock valuations and decisions for value-focused investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
IDEXX shows strong growth in CAG diagnostics and cloud software, but faces solvency concerns and macroeconomic pressures that may impact its future outlook.
Why It Matters
IDEXX's strong diagnostics growth and innovations may boost revenue, but solvency issues and macroeconomic pressures could impact future performance and stock stability.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Idexx (IDXX) recently announced earnings 30 days ago. Investors should monitor upcoming developments and performance for potential impacts on the stock.
Why It Matters
Earnings reports can influence stock prices based on performance and future guidance, impacting investor sentiment and potential price movements for Idexx (IDXX).
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
IDEXX Laboratories, Inc. (IDXX) presented at the 47th Annual Raymond James Institutional Investor Conference, sharing key updates and insights for investors.
Why It Matters
IDEXX's presentation at a major investor conference signals potential insights into its financial health and growth strategy, influencing market sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About IDXX Stock
What is IDEXX Laboratories, Inc.'s (IDXX) stock forecast for 2026?
Based on our analysis of 16 Wall Street analysts, IDEXX Laboratories, Inc. (IDXX) has a median price target of $775.00. The highest price target is $823.00 and the lowest is $470.00.
Is IDXX stock a good investment in 2026?
According to current analyst ratings, IDXX has 9 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $571.21. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IDXX stock?
Wall Street analysts predict IDXX stock could reach $775.00 in the next 12 months. This represents a 35.7% increase from the current price of $571.21. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is IDEXX Laboratories, Inc.'s business model?
The company generates revenue by developing, manufacturing, and distributing a range of diagnostic products and services tailored for veterinary and environmental sectors. Its offerings include in-clinic laboratory analyzers, pet-side tests, and veterinary practice management software, which are sold to veterinarians and animal hospitals. Additionally, IDEXX provides water testing products and diagnostics for livestock, poultry, and dairy, further diversifying its income streams.
What is the highest forecasted price for IDXX IDEXX Laboratories, Inc.?
The highest price target for IDXX is $823.00 from at , which represents a 44.1% increase from the current price of $571.21.
What is the lowest forecasted price for IDXX IDEXX Laboratories, Inc.?
The lowest price target for IDXX is $470.00 from Steve Chesney at Atlantic Equities, which represents a -17.7% decrease from the current price of $571.21.
What is the overall IDXX consensus from analysts for IDEXX Laboratories, Inc.?
The overall analyst consensus for IDXX is bullish. Out of 16 Wall Street analysts, 9 rate it as Buy, 5 as Hold, and 1 as Sell, with a median price target of $775.00.
How accurate are IDXX stock price projections?
Stock price projections, including those for IDEXX Laboratories, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 11:52 AM UTC